Blueprint Medicines Corporation announced that the U.S. Food and Dru Administration (FDA) has approved AYVAKIT (avapritinib) for the treatment of adults with indolent systemic mastocytosis (ISM)....
Blueprint Medicines Corporation announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) for AYVAKIT® (avapritinib) for...
